BACKGROUND: Frequency of drug changes in combination antiretroviral therapy among patients starting both tuberculosis (TB) and HIV therapy, as a result of treatment-limiting toxicity or virological failure, is not well established. METHODS:Patients in the Starting Antiretroviral Therapy at Three Points in Tuberculosis (SAPiT) trial were randomized to initiate antiretroviral therapy (ART) either early or late during TB treatment or after completion of TB treatment. Drug changes due to toxicity (defined as due to grade 3 or 4 adverse events) or virological failure (defined as viral load >1,000 copies/ml on two occasions, taken ≥4 weeks apart) were assessed in these patients. RESULTS: A total of 501 TB-HIV-coinfected patients were followed for a mean of 16.0 months (95% CI 15.5, 16.6) after ART initiation. The standard first-line antiretrovirals used were efavirenz, lamivudine and didanosine. Individual drug switches for toxicity occurred in 14 patients (incidence rate 2.1 per 100 person-years, 95% CI 1.1, 3.5), and complete regimen changes due to virological failure in 25 patients (incidence rate 3.7 per 100 person-years, 95% CI 2.4, 5.5). The most common treatment limiting toxicities were neuropsychiatric effects (n=4, 0.8%), elevated transaminase levels and hyperlactataemia (n=3, 0.6%), and peripheral neuropathy (n=2, 0.4%). Complete regimen change due to treatment failure was more common in patients with CD4(+) T-cell count <50 cells/mm(3) (P<0.001) at ART initiation and body mass index >25 kg/m(2) (P=0.01) at entry into the study. CONCLUSIONS: Both drug switches and complete regimen change were uncommon in patients cotreated for TB-HIV with the chosen regimen. Patients with severe immunosuppression need to be monitored carefully, as they were most at risk for treatment failure requiring regimen change.
RCT Entities:
BACKGROUND: Frequency of drug changes in combination antiretroviral therapy among patients starting both tuberculosis (TB) and HIV therapy, as a result of treatment-limiting toxicity or virological failure, is not well established. METHODS:Patients in the Starting Antiretroviral Therapy at Three Points in Tuberculosis (SAPiT) trial were randomized to initiate antiretroviral therapy (ART) either early or late during TB treatment or after completion of TB treatment. Drug changes due to toxicity (defined as due to grade 3 or 4 adverse events) or virological failure (defined as viral load >1,000 copies/ml on two occasions, taken ≥4 weeks apart) were assessed in these patients. RESULTS: A total of 501 TB-HIV-coinfectedpatients were followed for a mean of 16.0 months (95% CI 15.5, 16.6) after ART initiation. The standard first-line antiretrovirals used were efavirenz, lamivudine and didanosine. Individual drug switches for toxicity occurred in 14 patients (incidence rate 2.1 per 100 person-years, 95% CI 1.1, 3.5), and complete regimen changes due to virological failure in 25 patients (incidence rate 3.7 per 100 person-years, 95% CI 2.4, 5.5). The most common treatment limiting toxicities were neuropsychiatric effects (n=4, 0.8%), elevated transaminase levels and hyperlactataemia (n=3, 0.6%), and peripheral neuropathy (n=2, 0.4%). Complete regimen change due to treatment failure was more common in patients with CD4(+) T-cell count <50 cells/mm(3) (P<0.001) at ART initiation and body mass index >25 kg/m(2) (P=0.01) at entry into the study. CONCLUSIONS: Both drug switches and complete regimen change were uncommon in patients cotreated for TB-HIV with the chosen regimen. Patients with severe immunosuppression need to be monitored carefully, as they were most at risk for treatment failure requiring regimen change.
Authors: Gillian L Dean; Simon G Edwards; Natalie J Ives; Gail Matthews; Emma F Fox; Lesley Navaratne; Martin Fisher; Graham P Taylor; Rob Miller; Chris B Taylor; Annemiek de Ruiter; Anton L Pozniak Journal: AIDS Date: 2002-01-04 Impact factor: 4.177
Authors: Tanuja N Gengiah; Nicholas H G Holford; Julia H Botha; Andrew L Gray; Kogieleum Naidoo; Salim S Abdool Karim Journal: Eur J Clin Pharmacol Date: 2011-11-23 Impact factor: 2.953
Authors: Brookie M Best; Miguel Goicoechea; Mallory D Witt; Loren Miller; Eric S Daar; Catherine Diamond; Jeremiah G Tilles; Carol A Kemper; Robert Larsen; Diane T Holland; Shelly Sun; Sonia Jain; Glenn Wagner; Edmund V Capparelli; J Allen McCutchan; Richard H Haubrich Journal: J Acquir Immune Defic Syndr Date: 2007-12-01 Impact factor: 3.731
Authors: W Phillip Law; Gregory J Dore; Chris J Duncombe; Apicha Mahanontharit; Mark A Boyd; Kiat Ruxrungtham; Joep M A Lange; Praphan Phanuphak; David A Cooper Journal: AIDS Date: 2003-10-17 Impact factor: 4.177
Authors: Matthew P Fox; Gilles Van Cutsem; Janet Giddy; Mhairi Maskew; Olivia Keiser; Hans Prozesky; Robin Wood; Miguel A Hernán; Jonathan A C Sterne; Matthias Egger; Andrew Boulle Journal: J Acquir Immune Defic Syndr Date: 2012-08-01 Impact factor: 3.731
Authors: Sarah K Rempel; Madalynn J Welch; Allison L Ludwig; M Joseph Phillips; Yochana Kancherla; Donald J Zack; David M Gamm; Timothy M Gómez Journal: Cell Rep Date: 2022-05-17 Impact factor: 9.995
Authors: Dorina Onoya; Alana T Brennan; Rebecca Berhanu; Liudmyla van der Berg; Thulasizwe Buthelezi; Matthew P Fox Journal: J Int AIDS Soc Date: 2016-12-22 Impact factor: 5.396
Authors: Kenneth Bridbord; Kristen H Weymouth; Ann Puderbaugh; Celia Wolfman; Christopher W Belter; Joel G Breman; Peter H Kilmarx Journal: Ann Glob Health Date: 2019-03-20 Impact factor: 2.462